Cargando…
Data on the DNA damaging and mutagenic potential of the BH3-mimetics ABT-263/Navitoclax and TW-37
Unfortunately, the mutagenic activities of chemotherapy and radiotherapy can provoke development of therapy-induced malignancies in cancer survivors. Non-mutagenic anti-cancer therapies may be less likely to trigger subsequent malignant neoplasms. Here we present data regarding the DNA damaging and...
Autores principales: | Green, Maja M., Shekhar, Tanmay M., Hawkins, Christine J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4773390/ https://www.ncbi.nlm.nih.gov/pubmed/26958630 http://dx.doi.org/10.1016/j.dib.2016.01.013 |
Ejemplares similares
-
Synergistic Effects of TW-37 and ABT-263 on Renal Cell Carcinoma Cells
por: Yu, Rui, et al.
Publicado: (2021) -
Antitumor effect of TW-37, a BH3 mimetic in human oral cancer
por: Ahn, Chi-Hyun, et al.
Publicado: (2019) -
BH3 mimetic ABT-263 enhances the anticancer effects of apigenin in tumor cells with activating EGFR mutation
por: Zhan, Yihong, et al.
Publicado: (2019) -
Navitoclax (ABT263) reduces inflammation and promotes chondrogenic phenotype by clearing senescent osteoarthritic chondrocytes in osteoarthritis
por: Yang, Hao, et al.
Publicado: (2020) -
Human Pluripotent Stem Cells and Derived Neuroprogenitors Display Differential Degrees of Susceptibility to BH3 Mimetics ABT-263, WEHI-539 and ABT-199
por: García, Carolina Paola, et al.
Publicado: (2016)